
1. ann intern med. 2011 aug 16;155(4):217-25. doi:
10.7326/0003-4819-155-4-201108160-00005.

oseltamivir compared chinese traditional therapy maxingshigan-yinqiaosan
in treatment h1n1 influenza: randomized trial.

wang c(1), cao b, liu qq, zou zq, liang za, gu l, dong jp, liang lr, li xw, hu k,
he xs, sun yh, y, yang t, cao zx, guo ym, wen xm, wang yg, liu yl, jiang ld.

author information: 
(1)beijing chao-yang hospital, beijing institute respiratory medicine, capital
medical university, beijing, china. cyh-birm@263.net

erratum in
    ann intern med. 2012 jan 3;156(1 pt 1):71.

comment in
    ann intern med. 2012 jan 17;156(2):166; author reply 166-7.

background: observational studies asia suggest maxingshigan-yinqiaosan 
may effective treatment acute h1n1 influenza.
objective: compare efficacy safety oseltamivir and
maxingshigan-yinqiaosan treating uncomplicated h1n1 influenza.
design: prospective, nonblinded, randomized, controlled trial.
(clinicaltrials.gov registration number: nct00935194)
setting: eleven hospitals 4 provinces china.
patients: 410 persons [corrected] aged 15 69 [corrected] years with
laboratory-confirmed h1n1 influenza.
intervention: oseltamivir, 75 mg twice daily; maxingshigan-yinqiaosan decoction
(composed 12 chinese herbal medicines, including honey-fried herba ephedrae), 
200 ml 4 times daily; oseltamivir plus maxingshigan-yinqiaosan; no
intervention (control). interventions control given 5 days.
measurements: primary outcome time fever resolution. secondary outcomes
included symptom scores viral shedding determined using real-time reverse 
transcriptase polymerase chain reaction.
results: significant reductions estimated median time fever resolution 
compared control group (26.0 hours [95% ci, 24.0 33.0 hours]) were
seen oseltamivir (34% [95% ci, 20% 46%]; p < 0.001),
maxingshigan-yinqiaosan (37% [ci, 23% 49%]; p < 0.001), oseltamivir plus
maxingshigan-yinqiaosan (47% [ci, 35% 56%]; p < 0.001). time fever
resolution reduced 19% (ci, 0.3% 34%; p = 0.05) oseltamivir plus
maxingshigan-yinqiaosan compared oseltamivir. interventions control 
did differ terms decrease symptom scores (p = 0.38). two patients
who received maxingshigan-yinqiaosan reported nausea vomiting.
limitations: participants young mild h1n1 influenza virus infection.
missing viral data precluded definitive conclusions viral shedding.
conclusion: oseltamivir maxingshigan-yinqiaosan, alone combination,
reduced time fever resolution patients h1n1 influenza virus infection.
these data suggest maxingshigan-yinqiaosan may used alternative
treatment h1n1 influenza virus infection.
primary funding source: beijing science technology project beijing nova
program.

doi: 10.7326/0003-4819-155-4-201108160-00005 
pmid: 21844547  [indexed medline]

